Literature DB >> 21334023

Urinary PCA3 score predicts prostate cancer multifocality.

Virginie Vlaeminck-Guillem1, Marian Devonec, Marc Colombel, Claire Rodriguez-Lafrasse, Myriam Decaussin-Petrucci, Alain Ruffion.   

Abstract

PURPOSE: The urinary PCA3 gene test has proved helpful for deciding whether to (re)biopsy to diagnose prostate cancer. We searched for pathological features that influence the shedding of PCA3 producing prostate cancer cells in urine after digital rectal examination.
MATERIALS AND METHODS: Included in our study were 102 patients with an informative PCA3 score on the Progensa® PCA3 assay who underwent radical prostatectomy. Correlations were evaluated between PCA3 score and histopathological factors on prostatectomy, including tumor site in the prostate and the number of cancer foci.
RESULTS: PCA3 score significantly correlated with total tumor volume in prostatectomy specimens (p <0.001) but not with prostatectomy Gleason score or pathological stage. PCA3 score positively correlated with apical and basal invasion, and with bilaterality and multifocality. On multivariate analysis multifocality was an independent factor influencing PCA3 score (p = 0.012).
CONCLUSIONS: Site in the prostate gland and the number of cancer foci may explain the observed PCA3 score variation in patients operated on for prostate cancer. The PCA3 test could be helpful in preoperatively selecting patients with unifocal and unilateral cancer who could benefit from active surveillance or focal therapy.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21334023     DOI: 10.1016/j.juro.2010.11.072

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

Review 1.  Addressing the need for repeat prostate biopsy: new technology and approaches.

Authors:  Michael L Blute; E Jason Abel; Tracy M Downs; Frederick Kelcz; David F Jarrard
Journal:  Nat Rev Urol       Date:  2015-07-14       Impact factor: 14.432

2.  Additional value of PCA3 density to predict initial prostate biopsy outcome.

Authors:  A Ruffion; P Perrin; M Devonec; D Champetier; M Decaussin; P Paparel; V Vlaeminck-Guillem
Journal:  World J Urol       Date:  2014-02-06       Impact factor: 4.226

3.  Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer.

Authors:  John V Hegde; Darlene Veruttipong; Jonathan W Said; Robert E Reiter; Michael L Steinberg; Christopher R King; Amar U Kishan
Journal:  Urology       Date:  2017-05-25       Impact factor: 2.649

4.  Review of the literature: PCA3 for prostate cancer risk assessment and prognostication.

Authors:  Stacy Loeb; Alan W Partin
Journal:  Rev Urol       Date:  2011

5.  PCA3 and PCA3-based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy.

Authors:  Alain Ruffion; Marian Devonec; Denis Champetier; Myriam Decaussin-Petrucci; Claire Rodriguez-Lafrasse; Philippe Paparel; Paul Perrin; Virginie Vlaeminck-Guillem
Journal:  Int J Mol Sci       Date:  2013-08-29       Impact factor: 5.923

6.  The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer.

Authors:  Ana Emília Goulart Lemos; Aline da Rocha Matos; Luciana Bueno Ferreira; Etel Rodrigues Pereira Gimba
Journal:  Oncotarget       Date:  2019-11-12

7.  Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.

Authors:  Allison Young; Nallasivam Palanisamy; Javed Siddiqui; David P Wood; John T Wei; Arul M Chinnaiyan; Lakshmi P Kunju; Scott A Tomlins
Journal:  Am J Clin Pathol       Date:  2012-11       Impact factor: 2.493

8.  Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness.

Authors:  Lucile Tallon; Devillier Luangphakdy; Alain Ruffion; Marc Colombel; Marian Devonec; Denis Champetier; Philippe Paparel; Myriam Decaussin-Petrucci; Paul Perrin; Virginie Vlaeminck-Guillem
Journal:  Int J Mol Sci       Date:  2014-07-30       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.